EXOZ (eXoZymes Inc) Short-Term Debt to Capital

The price trajectory of eXoZymes Inc (EXOZ) shown below represents an asset striving for leadership in patent law and bioprocess efficiency. eXoZymes Inc develops advanced cell-free systems for producing renewable substances by leveraging biocatalyst modification. Its strategy is based on integrating synthetic biology into the production of fuels and chemicals, with a metric of 0.14, providing the foundation for sustainable manufacturing.

This indicator determines the proportion of short-term borrowings relative to equity, measuring the dependence of eXoZymes Inc (EXOZ) on the rapid repayment of funds. By analyzing the current level of short-term liabilities to equity, investors assess liquidity risk and the probability of cash flow gaps. An increase in this metric may indicate the financing of upgrades for automated reactors in California laboratories. An optimal balance of this ratio confirms the stability of the cell-free synthesis model and the efficient use of contract manufacturing sites.